Brief: Neuropace Announces First Patient Implanted In Nautilus Pivotal Study For The Treatment Of Idiopathic Generalized Epilepsy (IGE)
11/10/2022 13:19
Oct 11 (Reuters) - Neuropace Inc NPCE.O :
* NEUROPACE ANNOUNCES FIRST PATIENT IMPLANTED IN NAUTILUS
PIVOTAL
STUDY FOR THE TREATMENT OF IDIOPATHIC GENERALIZED EPILEPSY (IGE)
Source text for Eikon: ID:nBw3KwS6ha
Further company coverage: NPCE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NeuroPace
See all newsMedTech growth concerns likely to overshadow Q3 results, Leerink says
NeuroPace, Inc. reports results for the quarter ended June 30 - Earnings Summary
NeuroPace Q2 revenue slightly beats estimates
Brief: NeuroPace, Inc. Q2 EPS USD -0.18
NeuroPace, Inc. expected to post a loss of 21 cents a share - Earnings Preview